Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.
This statement is based on a regulatory approval from the Health Products Regulatory Authority:
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.